title: Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma.
authors.forename: Santiago
authors.initials: S
authors.lastname: Vivas
authors.forename: José María
authors.initials: JM
authors.lastname: Ruiz de Morales
authors.forename: Fernando
authors.initials: F
authors.lastname: Ramos
authors.forename: Dimas
authors.initials: D
authors.lastname: Suárez-Vilela
mesh_terms: D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002446:Celiac Disease / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D004379:Duodenal Neoplasms / Q000517:prevention & control; D004386:Duodenum / Q000473:pathology*; D005260:Female; D006801:Humans; D016399:Lymphoma, T-Cell / Q000517:prevention & control*; D008875:Middle Aged
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab